Algeta has announced that Apharadin met its primary endpoint in a bone marker analysis in a phase II hormone-refractory prostate cancer trial, demonstrating its potential in bone metastases. However, this must be translated into survival and/or quality-of-life advantage to guarantee a successful launch. Algeta must also find a suitable marketing partner to bring the product to the market.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions